{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:31:06Z","timestamp":1791919866667,"version":"4.3.4"},"reference-count":50,"publisher":"Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,6]]},"DOI":"10.31744\/einstein_journal\/2023rw0231","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T13:44:50Z","timestamp":1686145490000},"source":"Crossref","is-referenced-by-count":7,"title":["HIV and neoplasms: What do we know so far?"],"prefix":"10.31744","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7116-9562","authenticated-orcid":false,"given":"Thais Faria de","family":"Souza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9564-6098","authenticated-orcid":false,"given":"Yasmin Vianna","family":"Sym","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2409-5871","authenticated-orcid":false,"given":"Ethel Zimberg","family":"Chehter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16942","reference":[{"key":"key20230607094427_B1","author":"UNAIDS Brasil","year":"2023","unstructured":"1. UNAIDS Brasil. Estat\u00edsticas. Estat\u00edsticas globais sobre HIV 2021. Bras\u00edlia (DF): UNAIDS Brasil; 2023 [citado 2020 Dez 13]. Dispon\u00edvel em: https:\/\/unaids.org.br\/estatisticas\/","journal-title":"Estat\u00edsticas globais sobre HIV 2021"},{"issue":"8","key":"key20230607094427_B2","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0165-6147(02)02054-0","article-title":"Targeting HIV: antiretroviral therapy and development of drug resistance","volume":"23","author":"Men\u00e9ndez-Arias","year":"2002","unstructured":"2. Men\u00e9ndez-Arias L. Targeting HIV: antiretroviral therapy and development of drug resistance. Trends Pharmacol Sci. 2002;23(8):381-8.","journal-title":"Trends Pharmacol Sci"},{"issue":"5","key":"key20230607094427_B3","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1086\/596756","article-title":"HIV-associated opportunistic infections-going, going, but not gone: the continued need for prevention and treatment guidelines","volume":"48","author":"Brooks","year":"2009","unstructured":"3. Brooks JT, Kaplan JE, Holmes KK, Benson C, Pau A, Masur H. HIV-associated opportunistic infections-going, going, but not gone: the continued need for prevention and treatment guidelines. Clin Infect Dis. 2009;48(5):609-1.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"key20230607094427_B4","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/cncr.20354","article-title":"Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy","volume":"101","author":"Bonnet","year":"2004","unstructured":"4. Bonnet F, Lewden C, May T, Heripret L, Jougla E, Bevilacqua S, et al. Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. Cancer. 2004;101(2):317-24.","journal-title":"Cancer"},{"key":"key20230607094427_B5","first-page":"173","article-title":"Cancer prevention in HIV-infected populations. Seminars in oncology","author":"Goncalves","year":"2016","unstructured":"5. Goncalves PH, Montezuma-Rusca JM, Yarchoan R, Uldrick TS. Cancer prevention in HIV-infected populations. Seminars in oncology. Elsevier; 2016. pp. 173-88.","journal-title":"Elsevier"},{"issue":"9119","key":"key20230607094427_B6","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/S0140-6736(97)09028-4","article-title":"Spectrum of AIDS-associated malignant disorders","volume":"351","author":"Goedert","year":"1998","unstructured":"6. Goedert JJ, Cot\u00e9 TR, Virgo P, Scoppa SM, Kingma DW, Gail MH, et al. Spectrum of AIDS-associated malignant disorders. Lancet. 1998;351(9119):1833-9.","journal-title":"Lancet"},{"issue":"1","key":"key20230607094427_B7","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/COH.0000000000000327","article-title":"Evolving epidemiology of HIV-associated malignancies","volume":"12","author":"Shiels","year":"2017","unstructured":"7. Shiels MS, Engels EA. Evolving epidemiology of HIV-associated malignancies. Curr Opin HIV AIDS. 2017;12(1):6-11.","journal-title":"Curr Opin HIV AIDS"},{"issue":"10","key":"key20230607094427_B8","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"62","author":"Liberati","year":"2009","unstructured":"8. Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1-34.","journal-title":"J Clin Epidemiol"},{"key":"key20230607094427_B9","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.4103\/0971-5916.191813","article-title":"Spectrum of AIDS defining & non-AIDS defining malignancies in north India","volume":"143","author":"Sachdeva","year":"2016","unstructured":"9. Sachdeva RK, Sharma A, Singh S, Varma S. Spectrum of AIDS defining & non-AIDS defining malignancies in north India. Indian J Med Res. 2016; 143(Suppl):S129-35.","journal-title":"Indian J Med Res"},{"issue":"3","key":"key20230607094427_B10","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/sj.bjc.6605756","article-title":"Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV cohort study","volume":"103","author":"Franceschi","year":"2010","unstructured":"10. Franceschi S, Lise M, Clifford GM, Rickenbach M, Levi F, Maspoli M, et al. Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV cohort study. Br J Cancer. 2010;103(3):416-22.","journal-title":"Br J Cancer"},{"issue":"3","key":"key20230607094427_B11","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/jso.21590","article-title":"Ten years later: a single hospital experience with malignancy in HIV\/AIDS","volume":"102","author":"Reed","year":"2010","unstructured":"11. Reed M, Cosgrove JM, Cindrich R, Parithivel VS, Gad Y, Bangalore M, et al. Ten years later: a single hospital experience with malignancy in HIV\/AIDS. J Surg Oncol. 2010;102(3):282-6.","journal-title":"J Surg Oncol"},{"issue":"6","key":"key20230607094427_B12","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/ijc.25153","article-title":"Cancer incidence in people with AIDS in Italy","volume":"127","author":"Polesel","year":"2010","unstructured":"12. Polesel J, Franceschi S, Suligoi B, Crocetti E, Falcini F, Guzzinati S, et al. Cancer incidence in people with AIDS in Italy. Int J Cancer. 2010;127(6):1437-45.","journal-title":"Int J Cancer"},{"issue":"12","key":"key20230607094427_B13","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1002\/ijc.26332","article-title":"Ten-year survival among HIV-1-infected subjects with AIDS or non-AIDS-defining malignancies","volume":"130","author":"Spagnuolo","year":"2012","unstructured":"13. Spagnuolo V, Galli L, Salpietro S, Gianotti N, Guffanti M, Cossarini F, et al. Ten-year survival among HIV-1-infected subjects with AIDS or non-AIDS-defining malignancies. Int J Cancer. 2012;130(12):2990-6.","journal-title":"Int J Cancer"},{"issue":"9","key":"key20230607094427_B14","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/jnci\/djr076","article-title":"Cancer burden in the HIV-infected population in the United States","volume":"103","author":"Shiels","year":"2011","unstructured":"14. Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst. 2011;103(9):753-62.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"key20230607094427_B15","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/cncr.25547","article-title":"Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States","volume":"117","author":"Simard","year":"2011","unstructured":"15. Simard EP, Pfeiffer RM, Engels EA. Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States. Cancer. 2011;117(5):1089-96.","journal-title":"Cancer"},{"issue":"12","key":"key20230607094427_B16","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1097\/QAD.0b013e32833b1b26","article-title":"Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients","volume":"24","author":"Achhra","year":"2010","unstructured":"16. Achhra AC, Amin J, Law MG, Emery S, Gerstoft J, Gordin FM, et al. Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients. AIDS Lond Engl. 2010;24(12):1877-86.","journal-title":"AIDS Lond Engl"},{"issue":"5","key":"key20230607094427_B17","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/cid\/cit369","article-title":"Incidence and timing of cancer in HIV-infected individuals following initiation of combination antiretroviral therapy","volume":"57","author":"Yanik","year":"2013","unstructured":"17. Yanik EL, Napravnik S, Cole SR, Achenbach CJ, Gopal S, Olshan A, et al. Incidence and timing of cancer in HIV-infected individuals following initiation of combination antiretroviral therapy. Clin Infect Dis Off Publ Infect Dis Soc Am. 2013;57(5):756-64.","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"4","key":"key20230607094427_B18","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/QAI.0b013e318282a189","article-title":"Trends and predictors of non-AIDS-defining cancers in men and women with HIV infection: a single-institution retrospective study before and after the introduction of HAART","volume":"62","author":"Franzetti","year":"2013","unstructured":"18. Franzetti M, Adorni F, Parravicini C, Vergani B, Antinori S, Milazzo L, et al. Trends and predictors of non-AIDS-defining cancers in men and women with HIV infection: a single-institution retrospective study before and after the introduction of HAART. J Acquir Immune Defic Syndr. 2013;62(4):414-20.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"key20230607094427_B19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jiph.2014.08.003","article-title":"Assessing the impact of HAART on the incidence of defining and non-defining AIDS cancers among patients with HIV\/AIDS: a systematic review","volume":"8","author":"Cobucci","year":"2015","unstructured":"19. Cobucci RN, Lima PH, Souza PC, Costa VV, Cornetta MC, Fernandes JV, et al. Assessing the impact of HAART on the incidence of defining and non-defining AIDS cancers among patients with HIV\/AIDS: a systematic review. J Infect Public Health. 2015;8(1):1-10. Review.","journal-title":"J Infect Public Health"},{"issue":"5","key":"key20230607094427_B20","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1089\/aid.2014.0279","article-title":"Short Communication: HIV RNA Levels Predict AIDS-Defining and Non-AIDS-Defining Cancers After Antiretroviral Therapy Initiation Among HIV-Infected Adults","volume":"31","author":"Crum-Cianflone","year":"2015","unstructured":"20. Crum-Cianflone NF, Wang X, Ganesan A, Okulicz J, Weintrob A, Lalani T, et al. Short Communication: HIV RNA Levels Predict AIDS-Defining and Non-AIDS-Defining Cancers After Antiretroviral Therapy Initiation Among HIV-Infected Adults. AIDS Res Hum Retroviruses. 2015;31(5):514-8.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"7","key":"key20230607094427_B21","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1080\/09540121.2015.1011074","article-title":"Trends in cancer diagnoses and survival among persons with AIDS in a high HIV prevalence urban area","volume":"27","author":"Castel","year":"2015","unstructured":"21. Castel AD, Young H, Akiwumi AM, Vargas A, Rogers K, West T, et al. Trends in cancer diagnoses and survival among persons with AIDS in a high HIV prevalence urban area. AIDS Care. 2015;27(7):860-9.","journal-title":"AIDS Care"},{"issue":"11","key":"key20230607094427_B22","doi-asserted-by":"crossref","first-page":"e495","DOI":"10.1016\/S2352-3018(17)30125-X","article-title":"Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study","volume":"4","author":"Hern\u00e1ndez-Ram\u00edrez","year":"2017","unstructured":"22. Hern\u00e1ndez-Ram\u00edrez RU, Shiels MS, Dubrow R, Engels EA. Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study. Lancet HIV. 2017;4(11):e495-504.","journal-title":"Lancet HIV"},{"issue":"12","key":"key20230607094427_B23","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1177\/0956462417692924","article-title":"Trends in the incidence of AIDS-defining and non-AIDS-defining cancers in people living with AIDS: a population-based study from S\u00e3o Paulo, Brazil","volume":"28","author":"Tanaka","year":"2017","unstructured":"23. Tanaka LF, Latorre MD, Gutierrez EB, Heumann C, Herbinger KH, Froeschl G. Trends in the incidence of AIDS-defining and non-AIDS-defining cancers in people living with AIDS: a population-based study from S\u00e3o Paulo, Brazil. Int J STD AIDS. 2017;28(12):1190-8.","journal-title":"Int J STD AIDS"},{"issue":"5","key":"key20230607094427_B24","doi-asserted-by":"crossref","first-page":"572","DOI":"10.5858\/arpa.2019-0144-OA","article-title":"Trends in mortality from human immunodeficiency virus infection, 1984-2016: an autopsy-based study","volume":"144","author":"Nizami","year":"2020","unstructured":"24. Nizami S, Morales C, Hu K, Holzman R, Rapkiewicz A. Trends in mortality from human immunodeficiency virus infection, 1984-2016: an autopsy-based study. Arch Pathol Lab Med. 2020;144(5):572-9.","journal-title":"Arch Pathol Lab Med"},{"issue":"6","key":"key20230607094427_B25","doi-asserted-by":"crossref","first-page":"768","DOI":"10.7326\/M20-5226","article-title":"Risk for Non-AIDS-Defining and AIDS-Defining Cancer of Early Versus Delayed Initiation of Antiretroviral Therapy: a Multinational Prospective Cohort Study","volume":"174","author":"Chammartin","year":"2021","unstructured":"25. Chammartin F, Lodi S, Logan R, Ryom L, Mocroft A, Kirk O, d\u2019Arminio Monforte A, Reiss P, Phillips A, El-Sadr W, Hatleberg CI, Pradier C, Bonnet F, Law M, De Wit S, Sabin C, Lundgren JD, Bucher HC; D:A:D Study Group. Risk for Non-AIDS-Defining and AIDS-Defining Cancer of Early Versus Delayed Initiation of Antiretroviral Therapy: a Multinational Prospective Cohort Study. Ann Intern Med. 2021;174(6):768-76.","journal-title":"Ann Intern Med"},{"issue":"2","key":"key20230607094427_B26","doi-asserted-by":"crossref","first-page":"118","DOI":"10.4103\/ijstd.IJSTD_28_19","article-title":"Spectrum of malignancies among human immunodeficiency virus-infected patients at a tertiary level human immunodeficiency virus-anti-retroviral therapy center in a North Indian hospital","volume":"42","author":"Arora","year":"2021","unstructured":"26. Arora S, Mahesh A, Mahesh NK, Verma N. Spectrum of malignancies among human immunodeficiency virus-infected patients at a tertiary level human immunodeficiency virus-anti-retroviral therapy center in a North Indian hospital. Indian J Sex Transm Dis AIDS. 2021;42(2):118-24.","journal-title":"Indian J Sex Transm Dis AIDS"},{"issue":"5","key":"key20230607094427_B27","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/QAD.0b013e3283365356","article-title":"Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV","volume":"24","author":"Neuhaus","year":"2010","unstructured":"27. Neuhaus J, Angus B, Kowalska JD, La Rosa A, Sampson J, Wentworth D, Mocroft A; INSIGHT SMART and ESPRIT study groups. Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. AIDS. 2010;24(5):697-706.","journal-title":"AIDS"},{"issue":"6","key":"key20230607094427_B28","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1590\/S0036-46652011000600002","article-title":"Benign and malignant neoplasias in 261 necropsies for HIV-positive patients in the period of 1989 to 2008","volume":"53","author":"Micheletti","year":"2011","unstructured":"28. Micheletti AR, Macedo AC, Silva GB, Silva AC, Silva-Vergara ML, Murta EF, et al. Benign and malignant neoplasias in 261 necropsies for HIV-positive patients in the period of 1989 to 2008. Rev Inst Med Trop Sao Paulo. 2011;53(6):309-14.","journal-title":"Rev Inst Med Trop Sao Paulo"},{"issue":"10","key":"key20230607094427_B29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta4100","article-title":"Publication and related biases","volume":"4","author":"Song","year":"2000","unstructured":"29. Song F, Eastwood AJ, Gilbody S, Duley L, Sutton AJ. Publication and related biases. Health Technol Assess. 2000;4(10):1-115.","journal-title":"Health Technol Assess"},{"issue":"14","key":"key20230607094427_B30","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1097\/QAD.0000000000000382","article-title":"Risk of non-AIDS-defining cancers among HIV-1-infected individuals in France between 1997 and 2009: results from a French cohort","volume":"28","author":"Hleyhel","year":"2014","unstructured":"30. Hleyhel M, Hleyhel M, Bouvier AM, Belot A, Tattevin P, Pacanowski J, Genet P, De Castro N, Berger JL, Dupont C, Lavol\u00e9 A, Pradier C, Salmon D, Simon A, Martinez V, Spano JP, Costagliola D, Grabar S; Cancer Risk Group of the French Hospital Database on HIV (FHDH-ANRS CO4). Risk of non-AIDS-defining cancers among HIV-1-infected individuals in France between 1997 and 2009: results from a French cohort. AIDS. 2014;28(14):2109-18.","journal-title":"AIDS"},{"issue":"7","key":"key20230607094427_B31","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1080\/09540121.2015.1011074","article-title":"Trends in cancer diagnoses and survival among persons with AIDS in a high HIV prevalence urban area","volume":"27","author":"Castel","year":"2015","unstructured":"31. Castel AD, Young H, Akiwumi AM, Vargas A, Rogers K, West T, et al. Trends in cancer diagnoses and survival among persons with AIDS in a high HIV prevalence urban area. AIDS Care. 2015;27(7):860-9.","journal-title":"AIDS Care"},{"issue":"3","key":"key20230607094427_B32","doi-asserted-by":"crossref","first-page":"209","DOI":"10.5501\/wjv.v4.i3.209","article-title":"Non-acquired immunodeficiency syndrome definings malignancies among human immunodeficiency virus-positive subjects: epidemiology and outcome after two decades of HAART era","volume":"4","author":"Brugnaro","year":"2015","unstructured":"32. Brugnaro P, Morelli E, Cattelan F, Petrucci A, Panese S, Eseme F, et al. Non-acquired immunodeficiency syndrome definings malignancies among human immunodeficiency virus-positive subjects: epidemiology and outcome after two decades of HAART era. World J Virol. 2015;4(3):209-18.","journal-title":"World J Virol"},{"issue":"17","key":"key20230607094427_B33","doi-asserted-by":"crossref","first-page":"5183","DOI":"10.1158\/1078-0432.CCR-07-0161","article-title":"Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo","volume":"13","author":"Gills","year":"2007","unstructured":"33. Gills JJ, Lopiccolo J, Tsurutani J, Shoemaker RH, Best CJ, Abu-Asab MS, et al. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res. 2007;13(17):5183-94.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"key20230607094427_B34","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02635-18","article-title":"Halogen Bond Interactions of Novel HIV-1 Protease Inhibitors (PI) (GRL-001-15 and GRL-003-15) with the Flap of Protease Are Critical for Their Potent Activity against Wild-Type HIV-1 and Multi-PI-Resistant Variants","volume":"63","author":"Hattori","year":"2019","unstructured":"34. Hattori SI, Hayashi H, Bulut H, Rao KV, Nyalapatla PR, Hasegawa K, et al. Halogen Bond Interactions of Novel HIV-1 Protease Inhibitors (PI) (GRL-001-15 and GRL-003-15) with the Flap of Protease Are Critical for Their Potent Activity against Wild-Type HIV-1 and Multi-PI-Resistant Variants. Antimicrob Agents Chemother. 2019;63(6):e02635-18.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"key20230607094427_B35","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1470-2045(03)01192-6","article-title":"Use of HIV protease inhibitors to block Kaposi\u2019s sarcoma and tumour growth","volume":"4","author":"Sgadari","year":"2003","unstructured":"35. Sgadari C, Monini P, Barillari G, Ensoli B. Use of HIV protease inhibitors to block Kaposi\u2019s sarcoma and tumour growth. Lancet Oncol. 2003;4(9):537-47.","journal-title":"Lancet Oncol"},{"issue":"7","key":"key20230607094427_B36","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/cncr.21334","article-title":"Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals","volume":"104","author":"Burgi","year":"2005","unstructured":"36. Burgi A, Brodine S, Wegner S, Milazzo M, Wallace MR, Spooner K, et al. Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer. 2005;104(7):1505-11.","journal-title":"Cancer"},{"key":"key20230607094427_B37","author":"International Agency for Research on Cancer (IARC)","year":"2000","unstructured":"37. International Agency for Research on Cancer (IARC). Working Group on the Evaluation of Carcinogenic Risks to Humans. Some Antiviral and Antineoplastic Drugs, and Other Pharmaceutical Agents. Lyon (FR): IARC; 2000. (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, No. 76.) [cited 2022 Dec 27]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK401398\/","journal-title":"Some Antiviral and Antineoplastic Drugs, and Other Pharmaceutical Agents"},{"issue":"6","key":"key20230607094427_B38","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2008.19.6626","article-title":"Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection","volume":"27","author":"Powles","year":"2009","unstructured":"38. Powles T, Robinson D, Stebbing J, Shamash J, Nelson M, Gazzard B, et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol. 2009;27(6):884-90.","journal-title":"J Clin Oncol"},{"issue":"12","key":"key20230607094427_B39","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/cid\/cir207","article-title":"Immunodeficiency as a risk factor for non-AIDS-defining malignancies in HIV-1-infected patients receiving combination antiretroviral therapy","volume":"52","author":"Kesselring","year":"2011","unstructured":"39. Kesselring A, Gras L, Smit C, van Twillert G, Verbon A, Wolf F, et al. Immunodeficiency as a risk factor for non-AIDS-defining malignancies in HIV-1-infected patients receiving combination antiretroviral therapy. Clin Infect Dis. 2011;52(12):1458-65.","journal-title":"Clin Infect Dis"},{"issue":"15","key":"key20230607094427_B40","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1001\/archinternmed.2010.253","article-title":"Spectrum of cancer risk late after AIDS onset in the United States","volume":"170","author":"Simard","year":"2010","unstructured":"40. Simard EP, Pfeiffer RM, Engels EA. Spectrum of cancer risk late after AIDS onset in the United States. Arch Intern Med. 2010;170(15):1337-45.","journal-title":"Arch Intern Med"},{"issue":"6","key":"key20230607094427_B41","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/jnci\/dji072","article-title":"Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy","volume":"97","author":"Clifford","year":"2005","unstructured":"41. Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, Rapiti E, Levi F, Jundt G, Fisch T, Bordoni A, De Weck D, Franceschi S; Swiss HIV Cohort. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005;97(6):425-32.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"key20230607094427_B42","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-017-3229-1","article-title":"Overview of cancer incidence and mortality among people living with HIV\/AIDS in British Columbia, Canada: Implications for HAART use and NADM development","volume":"17","author":"Chiu","year":"2017","unstructured":"42. Chiu CG, Smith D, Salters KA, Zhang W, Kanters S, Milan D, et al. Overview of cancer incidence and mortality among people living with HIV\/AIDS in British Columbia, Canada: Implications for HAART use and NADM development. BMC Cancer. 2017;17(1):270.","journal-title":"BMC Cancer"},{"key":"key20230607094427_B43","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2334-13-471","article-title":"Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study","volume":"13","author":"Worm","year":"2013","unstructured":"43. Worm SW, Bower M, Reiss P, Bonnet F, Law M, F\u00e4tkenheuer G, d\u2019Arminio Monforte A, Abrams DI, Grulich A, Fontas E, Kirk O, Furrer H, De Wit S, Phillips A, Lundgren JD, Sabin CA; D:A:D Study Group. Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study. BMC Infect Dis. 2013;13:471.","journal-title":"BMC Infect Dis"},{"issue":"6","key":"key20230607094427_B44","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.ejca.2008.11.005","article-title":"Long-term survival expectations of cancer patients in Europe in 2000-2002","volume":"45","author":"Brenner","year":"2009","unstructured":"44. Brenner H, Francisci S, de Angelis R, Marcos-Gragera R, Verdecchia A, Gatta G, Allemani C, Ciccolallo L, Coleman M, Sant M; EUROCARE Working Group. Long-term survival expectations of cancer patients in Europe in 2000-2002. Eur J Cancer. 2009;45(6):1028-41.","journal-title":"Eur J Cancer"},{"issue":"2","key":"key20230607094427_B45","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1468-1293.2012.01038.x","article-title":"Cancer, immunodeficiency and antiretroviral treatment: results from the Australian HIV Observational Database (AHOD)","volume":"14","author":"Petoumenos","year":"2013","unstructured":"45. Petoumenos K, van Leuwen MT, Vajdic CM, Woolley I, Chuah J, Templeton DJ, Grulich AE, Law MG; Australian HIV Observational Database. Cancer, immunodeficiency and antiretroviral treatment: results from the Australian HIV Observational Database (AHOD). HIV Med. 2013;14(2):77-84.","journal-title":"HIV Med"},{"issue":"7","key":"key20230607094427_B46","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1086\/605594","article-title":"Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort","volume":"49","author":"Bruyand","year":"2009","unstructured":"46. Bruyand M, Thi\u00e9baut R, Lawson-Ayayi S, Joly P, Sasco AJ, Merci\u00e9 P, Pellegrin JL, Neau D, Dabis F, Morlat P, Ch\u00eane G, Bonnet F; Groupe d\u2019Epid\u00e9miologie Clinique du SIDA en Aquitaine (GECSA). Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort. Clin Infect Dis. 2009;49(7):1109-16.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"key20230607094427_B47","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/j.1365-2133.2010.09712.x","article-title":"Anal carcinoma in human immunodeficiency virus-positive men: results of a prospective study from Germany","volume":"162","author":"Kreuter","year":"2010","unstructured":"47. Kreuter A, Potthoff A, Brockmeyer NH, Gambichler T, Swoboda J, St\u00fccker M, Schmitt M, Pfister H, Wieland U; German Competence Network HIV\/AIDS. Anal carcinoma in human immunodeficiency virus-positive men: results of a prospective study from Germany. Br J Dermatol. 2010;162(6):1269-77.","journal-title":"Br J Dermatol"},{"issue":"19","key":"key20230607094427_B48","first-page":"6556","article-title":"Lung cancer mortality in relation to age, duration of smoking, and daily cigarette consumption: results from Cancer Prevention Study II","volume":"63","author":"Flanders","year":"2003","unstructured":"48. Flanders WD, Lally CA, Zhu BP, Henley SJ, Thun MJ. Lung cancer mortality in relation to age, duration of smoking, and daily cigarette consumption: results from Cancer Prevention Study II. Cancer Res. 2003;63(19):6556-62.","journal-title":"Cancer Res"},{"key":"key20230607094427_B49","first-page":"1377","volume-title":"Eur Rev Med Pharmacol Sci","author":"Pinzone","year":"2012","unstructured":"49. Pinzone MR, Fiorica F, Di Rosa M, Malaguarnera G, Malaguarnera L, Cacopardo B, et al. Non-AIDS-defining cancers among HIV-infected people. Eur Rev Med Pharmacol Sci. 2012;16(10):1377-88."},{"issue":"11","key":"key20230607094427_B50","doi-asserted-by":"crossref","first-page":"e495","DOI":"10.1016\/S2352-3018(17)30125-X","article-title":"Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study","volume":"4","author":"Hern\u00e1ndez-Ram\u00edrez","year":"2017","unstructured":"50. Hern\u00e1ndez-Ram\u00edrez RU, Shiels MS, Dubrow R, Engels EA. Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study. Lancet HIV. 2017;4(11):e495-504.","journal-title":"Lancet HIV"}],"container-title":["einstein (S\u00e3o Paulo)"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T13:45:52Z","timestamp":1686145552000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.einstein.br\/article\/hiv-and-neoplasms-what-do-we-know-so-far\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":50,"alternative-id":["10.31744\/einstein_journal\/2023RW0231"],"URL":"https:\/\/doi.org\/10.31744\/einstein_journal\/2023rw0231","relation":{},"ISSN":["1679-4508","2317-6385"],"issn-type":[{"value":"1679-4508","type":"print"},{"value":"2317-6385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"article-number":"eRW0231"}}